Tauklarify is a drug owned by Cerveau Technologies Inc A Lantheus Co. It is protected by 2 US drug patents filed in 2026 out of which none have expired yet. Tauklarify's patents will be open to challenges from 13 August, 2030. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 09, 2035. Details of Tauklarify's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9808542 | Pyrrolo[2,3-C]Pyridines As Imaging Agents For Neurofibrillary |
Jun, 2035
(8 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10022461 | Pyrrolo[2,3-C]Pyridines As Imaging Agents For Neurofibrilary Tangles |
Jun, 2035
(8 years from now) | Active |
FDA has granted several exclusivities to Tauklarify. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Tauklarify, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Tauklarify.
Exclusivity Information
Tauklarify holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Tauklarify's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2031 |
US patents provide insights into the exclusivity only within the United States, but
Tauklarify is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Tauklarify's family patents as well as insights into
ongoing legal events
on those patents.
Tauklarify's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tauklarify's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 09, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tauklarify Generics:
There are no approved generic versions for Tauklarify as of now.
About Tauklarify
Tauklarify is a drug owned by Cerveau Technologies Inc A Lantheus Co. Tauklarify uses Florquinitau F-18 as an active ingredient. Tauklarify was launched by Cerveau Lantheus in 2026.
Approval Date:
Tauklarify was approved by FDA for market use on 13 August, 2026.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Tauklarify is 13 August, 2026, its NCE-1 date is estimated to be 13 August, 2030.
Active Ingredient:
Tauklarify uses Florquinitau F-18 as the active ingredient. Check out other Drugs and Companies using Florquinitau F-18 ingredient
Dosage:
Tauklarify is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1-40mCi/ML | SOLUTION | Prescription | INTRAVENOUS |